Latest Conference Articles

As hematology and oncology pharmacists have become increasingly essential members of the care team, new investigational drugs could have a significant impact on the treatment landscape.

The researchers used cross-sectional surveys, which were conducted with a convenience sample of rural community pharmacists who were part of a rural community pharmacy practice-based research network.

The analysis found that more than twice as many women who received olaparib were still alive 5 years after the beginning of the study with no progression of their cancer.

DKN-01 is a humanized monoclonal antibody that binds to and blocks the activity of the Dickkopf-1 (DKK1) protein, which activates the innate immune system in the tumor microenvironment and anti-tumor activity.

The COVID-19 pandemic significantly impacted pharmacy practice due to its role in supporting overwhelmed physicians, nurses, and other health care professionals who faced some of the immediate challenges of the crisis.

Results from the phase 3 KEYNOTE-775/study 309 trial found that Keytruda plus Lenvima reduced risk of death by 38%, with a median overall survival of 18.3 months

When analyzing the odds of death or hospitalization due to COVID-19, the researchers found that use of cytotoxic chemotherapy did not predict increased risk for either.

The company received Fast Track designation from the FDA for GEN-1, a DNA-mediated interleukin-12 (IL-12) immunotherapy.

According to study results presented at the SGO meeting, biopsies showed no signs of cancer or precancer in two-thirds of 165 women with stage I endometrial cancer or atypical endometrial hyperplasia, 6 months after insertion of the hormonal IUD.

With a wide array of cannabidiol (CBD) and CBD extract products available without a prescription, pharmacists have an increasingly important role to play in counseling patients on which products may work for them and how they should be properly used.

Bennett is the seventh woman to be recognized for the award since its inception in 1919.

Results presented at the 2021 APhA Annual Meeting and Exposition cite advertising and marketing difficulties as main barrier to success of point-of-care service.

As a first-generation college graduate with a focus on providing care to underserved and low-income communities, new APhA President Sandra Leal said her main goal is to continue advocating for the pharmacy field.

Debu Tripathy, MD, University of Texas, MD Anderson Cancer Center at Houston, discussed the basic requirements of personalizing therapy.

The investigators performed a retrospective review of 215 patients age 65 years and older with TNBC or HER2+ breast cancer who underwent mastectomy from 2005 to 2020 at a single institution.

Angelo Moore, PhD, MSN, RN, NE-BC, program manager, Office of Health Equity at Duke Cancer Institute, discussed how one of his goals was to truly involve the community in educating others on the clinical guidance, primarily for prostate cancer screenings.

Due to new medications in discovery, the outcomes for patients with cancer are increasingly improving; however, the cost of this improved care is also increasing.

The Prevention on the Go program has detected more than 50 cases of cancer over a 4-year period.

Many rural areas identify with many barriers in their community, such as transportation, technology access, human factors, and the design of the health care model.

One way of approaching the process of allowing patients to self-report their symptoms is through an electronic patient-reported outcomes (ePRO) system.

Although there have been many challenges and concerns during the pandemic, experts said there are also lessons to be learned and implemented once the pandemic is over.

Data from the FIGHT trial suggests that approximately 30% of patients with non-human epidermal growth factor 2-positive GEJ cancers overexpress fibroblast growth factor receptor 2.

The efficacy results demonstrated that there were 4 patients with confirmed partial response, and an additional 3 patients had stable disease lasting 16 weeks or longer.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic the next steps for his CAEL-101 findings, a treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic his recent CAEL-101 findings, and how it can help shape treatment for patients living with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about what CAEL-101 is, how it works, and how it is used to treat patients with amyloid light chain amyloidosis.

Pharmacy Times interviewed Jason Valent, MD, of the Cleveland Clinic about his new research surrounding CAEL-101, a treatment for patients living with amyloid light chain amyloidosis.

Data from a phase 1b/2 trial investigating the treatment of CCA with the combination of silmitasertib plus gemcitabine and cisplatin in comparison with gemcitabine and cisplatin found a statistically significant difference.

The treatment of 5-fluorouracil with levofolinate and irinotecan was found to be well-tolerated and effective as a second-line treatment for patients with gemcitabine-refractory advanced pancreatic cancer.

Data from a phase 1b/2 study investigating onvansertib as a treatment of KRAS-mutated mCRC demonstrated that 42% of patients achieved a PR and 67% demonstrated a durable response ranging from 6.1 months to 13.7 months.